180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 1, 1998
April 21, 2020
99b50bce-632e-41dc-871f-60d4142d9386
Related Documents
Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act
Guidance DocumentMarch 27, 2000Center for Drug Evaluation and Research
Implementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees
Guidance DocumentOctober 1, 1998Center for Drug Evaluation and Research
Variations in Drug Products that May Be Included in a Single ANDA
Guidance DocumentDecember 1, 1998Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox